6 Results for "

c-Src Kinase-IN-1

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "c-Src Kinase-IN-1" in MCE Product Catalog:

Cat. No.: HY-208748
CAS No.: 1380088-01-6
Target:  

Src

Research Areas:  

Cancer

c-Src Kinase-IN-1 is a highly selective, cell-permeable inhibitor of c-Src kinase that suppresses cancer cell growth. c-Src Kinase-IN-1 has a Ki of 44 nM and a Kd value of 86 nM against chicken-derived c-Src. c-Src Kinase-IN-1 interacts with the phosphate-binding loop of c-Src and exhibits selectivity toward homologous Src family kinases and c-Abl. c-Src Kinase-IN-1 can be used in cancer-related research .
loading...
    loading...
Cat. No.: HY-137918
CAS No.: 666729-57-3
TGF-βRI inhibitor 3 (Compound 9ac) is a selective TGF-β inhibitor. TGF-βRI inhibitor 3 can effectively inhibit the TGF-β signaling pathway. TGF-βRI inhibitor 3 has IC50 values of 13 μM and 0.63 μM for c-Src kinase and ALK5 kinase, respectively .
loading...
    loading...
Cat. No.: HY-P2547A
Target:  

Src

Research Areas:  

Others

Tyrosine Kinase Peptide 1 (acetate) is a control substrate peptide for c-Src assay .
loading...
    loading...
Cat. No.: HY-P2547
CAS No.: 173691-86-6
Target:  

Src

Research Areas:  

Others

Tyrosine Kinase Peptide 1 is a control substrate peptide for c-Src assay .
loading...
    loading...
Cat. No.: HY-162952
Target:  

Bcr-Abl

Research Areas:  

Cancer

cSRC/BCR-ABL1-IN-1 (compund 16a) is a dual-target cSRC/BCR-ABL1 kinase inhibitor .
loading...
    loading...
Cat. No.: HY-184274
Target:  

Apoptosis EGFR Src

Research Areas:  

Cancer

EGFR/c-SRC-IN-1 is a blood-brain barrier-impermeable, ATP-competitive dual-target inhibitor of EGFR/c-SRC, with an IC50 of 0.05 μM against EGFR and an IC50 of 0.07 μM against c-SRC. EGFR/c-SRC-IN-1 shows selectivity toward ABL-2 and VEGFR-2 kinases. EGFR/c-SRC-IN-1 triggers endogenous apoptosis by upregulating p53 and Bax, downregulating Bcl-2, and altering the Bax/Bcl-2 ratio. EGFR/c-SRC-IN-1 can be used in the research of non-small cell lung cancer, hepatocellular carcinoma, and triple-negative breast cancer .
loading...
    loading...